Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

JBZ-001

Phase 1Small molecule

JJabez Bioscience, Inc

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid and Hematological MalignanciesRecruiting

Solid and Hematological MalignanciesPhase 1

Recruiting

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Solid and Hematological Malignancies

NCT06801002

Clinical

Trials by Indication[1]

Solid and Hematological Malignancies1 trial

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

Recruiting·JJabez Bioscience, Inc·Phase 1·NCT06801002·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JBZ-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JBZ-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JBZ-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jabez Bioscience, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJabez Bioscience, Inc

Related News